Rae Jessee, APRN
Family · Mays Lick, KYNPI 1154316065
Payments from drug & device makers
Across 138 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$1K
- AbbVie$557
- Lilly USA, LLC$286
- Medtronic$187
- GSK$162
- Corcept Therapeutics$148
- plus $900 from 20 others
What the payments were for
- Speaking & faculty fees$1,25037%
- Food & beverage$2,05962%
- Education$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 1 | $1,100 |
| AbbVie(2 entities) | 41 | $557 |
| Lilly USA, LLC | 13 | $286 |
| Medtronic | 4 | $187 |
| GSK | 10 | $162 |
| Corcept Therapeutics | 9 | $148 |
| Amgen | 9 | $119 |
| Novo Nordisk | 7 | $108 |
| Amarin Pharma, Inc. | 5 | $85 |
| Bayer | 5 | $76 |
| Mannkind Corporation | 5 | $73 |
| Esperion Therapeutics, Inc. | 5 | $71 |
| Xeris Pharmaceuticals, Inc. | 3 | $55 |
| Pfizer | 4 | $54 |
| IBSA Pharma Inc. | 3 | $44 |
| Exact Sciences | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $31 |
| Smith+Nephew | 1 | $16 |
| QOL Medical, LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
| Abbott | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| AstraZeneca | 1 | $12 |
| BETA Bionics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$1,100
- MINIMED 780G$150
- MOUNJARO$113
How this compares
$3,341 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 29 | $1,238,642 |
| MounjaroTirzepatide | 596 | $668,227 |
| OzempicSemaglutide | 392 | $497,600 |
| Tresiba Flextouch U-200Insulin Degludec | 279 | $434,400 |
| FarxigaDapagliflozin Propanediol | 213 | $283,996 |
| JardianceEmpagliflozin | 154 | $234,480 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 126 | $215,710 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 107 | $182,398 |
| TrulicityDulaglutide | 87 | $118,732 |
| Humulin R U-500Insulin Regular, Human | 56 | $95,768 |
| ForteoTeriparatide | 15 | $73,032 |
| EliquisApixaban | 49 | $56,454 |
| Repatha SureclickEvolocumab | 52 | $43,105 |
| TradjentaLinagliptin | 28 | $42,071 |
| MyrbetriqMirabegron | 45 | $40,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $148 | $1,238,64229 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $286 | $877,146737 claims |
| Novo NordiskOzempic, Novolog | $108 | $525,593456 claims |
| AstraZenecaFarxiga | $12 | $283,996213 claims |
| PfizerEliquis | $54 | $56,45449 claims |
| AbbVieLinzess, Synthroid | $557 | $40,669110 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $40,57645 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $162 | $36,09525 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $12 | $14,06614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.
Other family in Mays Lick
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.